INDICATORS ON AZD3965 YOU SHOULD KNOW

Hepatic impairment No dose adjustment is needed in sufferers with delicate or average (Baby-Pugh A or B) hepatic impairment (see segment 5.2). Exposure to midostaurin and its active metabolite CGP62221 is significantly lower in clients with serious hepatic impairment than that in clients with usual hepatic functionality (see portion five.can block